CSQR · Form EFFECT · Csquare, Inc.

⌘K

Filings	Filing Date	Form Type	Company	Description	AI	Link

CSQR · Form EFFECT · Csquare, Inc. | Signal8

Insider transactionsFund filings

Sort

Filings				Description
CDLRCadeler plc Nov 9, 2026 · 7:21 AM ET 6-K Cadeler plc announced on 9 November 2026 that it will exercise its rights under sections 7…	Nov 9, 20267:21 AM ET	6-K	CDLR Cadeler plc	Cadeler plc announced on 9 November 2026 that it will exercise its rights under sections 70 and 72 of the Danish Companies Act to compulsorily acquire the remaining minority shares…
CDLRCadeler A/S Nov 9, 2026 · 7:21 AM ET 6-K Cadeler plc has initiated a compulsory acquisition of all remaining Cadeler A/S minority s…	Nov 9, 20267:21 AM ET	6-K	CDLR Cadeler A/S	Cadeler plc has initiated a compulsory acquisition of all remaining Cadeler A/S minority shares under sections 70 and 72 of the Danish Companies Act, after the share-for-share exch…
TNXPTonix Pharmaceuticals Holding Corp. Nov 9, 2026 · 7:20 AM ET 8-K Tonix Pharmaceuticals reported Q3 2026 net product revenue of approximately $17.2 million,… 2.02Results of operations9.01ExhibitsExhibits:EX-99.01	Nov 9, 20267:20 AM ET	8-K	TNXP Tonix Pharmaceuticals Holding Corp.	2.02Results of operations9.01ExhibitsExhibits:EX-99.01 Tonix Pharmaceuticals reported Q3 2026 net product revenue of approximately $17.2 million, up from $3.3 million a year earlier, led by TONMYA net sales of roughly $15 million, up 3…
CGEMCullinan Therapeutics, Inc. Nov 9, 2026 · 7:20 AM ET 8-KCullinan Therapeutics announced positive interim clinical data from Genrix Bio's Phase 1b/… 7.01Reg FD8.01Other events9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:20 AM ET	8-K	CGEM Cullinan Therapeutics, Inc.	7.01Reg FD8.01Other events9.01ExhibitsExhibits:EX-99.1 Cullinan Therapeutics announced positive interim clinical data from Genrix Bio's Phase 1b/2a trial of velinotamig (BCMAxCD3 T cell engager) in refractory systemic lupus erythematos…
FTHFaeth Therapeutics, Inc. Nov 9, 2026 · 7:19 AM ET 8-KFaeth Therapeutics reported positive preliminary Phase 2 topline results for PIKTOR (serab… 7.01Reg FD9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:19 AM ET	8-K	FTH Faeth Therapeutics, Inc.	7.01Reg FD9.01ExhibitsExhibits:EX-99.1 Faeth Therapeutics reported positive preliminary Phase 2 topline results for PIKTOR (serabelisib plus sapanisertib) combined with paclitaxel in advanced endometrioid endometrial ca…
FACTFACT II Acquisition Corp. Nov 9, 2026 · 7:17 AM ET 8-KFACT II Acquisition Corp. filed an 8-K ahead of its November 17, 2026 extraordinary meetin… 8.01Other events9.01ExhibitsExhibits:EX-10.1	Nov 9, 20267:17 AM ET	8-K	FACT FACT II Acquisition Corp.	8.01Other events9.01ExhibitsExhibits:EX-10.1 FACT II Acquisition Corp. filed an 8-K ahead of its November 17, 2026 extraordinary meeting to approve extending its business combination deadline from November 27, 2026 to Novembe…
ROIVRoivant Sciences Ltd. Nov 9, 2026 · 7:17 AM ET 8-K Roivant reported its fiscal Q2 ended September 30, 2026, headlined by $31.0 million in net… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:17 AM ET	8-K	ROIV Roivant Sciences Ltd.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Roivant reported its fiscal Q2 ended September 30, 2026, headlined by $31.0 million in net product revenue from LISRAYA (brepocitinib) in its first 5 weeks following August 2026 FD…
ELBMElectra Battery Materials Corp Nov 9, 2026 · 7:15 AM ET 6-K Electra Battery Materials reported Q3 2026 net income of C$4.6M and nine-month net income… Exhibits:EX-99.1EX-99.2+3	Nov 9, 20267:15 AM ET	6-K	ELBM Electra Battery Materials Corp	Exhibits:EX-99.1EX-99.2+3 Electra Battery Materials reported Q3 2026 net income of C$4.6M and nine-month net income of C$41.8M, but both were driven almost entirely by a C$59.0M non-cash gain on revaluing i…
AIOTPowerfleet, Inc. Nov 9, 2026 · 7:13 AM ET 8-K Powerfleet reported record Q2 FY2027 revenue of $115.7 million, up 4% year-over-year, with… 2.02Results of operations7.01Reg FD9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20267:13 AM ET	8-K	AIOT Powerfleet, Inc.	2.02Results of operations7.01Reg FD9.01ExhibitsExhibits:EX-99.1EX-99.2 Powerfleet reported record Q2 FY2027 revenue of $115.7 million, up 4% year-over-year, with services revenue up 7% to $95.2 million (82% of mix). Adjusted EBITDA was roughly flat at…
TNGXTango Therapeutics, Inc. Nov 9, 2026 · 7:13 AM ET 8-K Tango Therapeutics reported a Q3 2026 net loss of $68.4 million ($0.39/share) versus net i… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:13 AM ET	8-K	TNGX Tango Therapeutics, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Tango Therapeutics reported a Q3 2026 net loss of $68.4 million ($0.39/share) versus net income of $15.9 million a year ago, as collaboration revenue fell to zero following the Aug…
BRCBRADY CORP Nov 9, 2026 · 7:11 AM ET 8-K Brady Corporation announced the election of Scott J. Robinson and Kenneth J. Spangler to i… 5.02Officer/director change9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:11 AM ET	8-K	BRC BRADY CORP	5.02Officer/director change9.01ExhibitsExhibits:EX-99.1 Brady Corporation announced the election of Scott J. Robinson and Kenneth J. Spangler to its Board of Directors, effective November 9, 2026, while director Patrick W. Allender will…
SGCSUPERIOR GROUP OF COMPANIES, INC. Nov 9, 2026 · 7:10 AM ET 8-K Superior Group of Companies (SGC) reported Q3 2026 net sales of $146.0 million, up 5% from… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:10 AM ET	8-K	SGC SUPERIOR GROUP OF COMPANIES, INC.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Superior Group of Companies (SGC) reported Q3 2026 net sales of $146.0 million, up 5% from $138.5 million a year ago, driven by growth in Branded Products and Contact Centers. Net…
AKAMAKAMAI TECHNOLOGIES INC Nov 9, 2026 · 7:10 AM ET 8-K Akamai announced on November 9, 2026 a proposed private offering of $1.1 billion of conver… 1.01Material agreement2.03Direct financial obligation8.01Other events+1Exhibits:EX-10.1EX-99.1	Nov 9, 20267:10 AM ET	8-K	AKAM AKAMAI TECHNOLOGIES INC	1.01Material agreement2.03Direct financial obligation8.01Other events+1Exhibits:EX-10.1EX-99.1 Akamai announced on November 9, 2026 a proposed private offering of $1.1 billion of convertible senior notes due 2028 and $1.1 billion due 2031, with initial purchasers holding opt…
IMVTImmunovant, Inc. Nov 9, 2026 · 7:09 AM ET 8-K Immunovant reported fiscal Q2 2026 results and clinical updates on November 9, 2026, ancho… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:09 AM ET	8-K	IMVT Immunovant, Inc.	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Immunovant reported fiscal Q2 2026 results and clinical updates on November 9, 2026, anchored by positive Phase 2 data for IMVT-1402 in difficult-to-treat rheumatoid arthritis. In…
OCULOCULAR THERAPEUTIX, INC Nov 9, 2026 · 7:08 AM ET 8-K Ocular Therapeutix (NASDAQ: OCUL) reported Q3 2026 results with total revenue of $12.9 mil… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:08 AM ET	8-K	OCUL OCULAR THERAPEUTIX, INC	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Ocular Therapeutix (NASDAQ: OCUL) reported Q3 2026 results with total revenue of $12.9 million, down from $14.5 million a year ago, and a net loss of $94.8 million ($0.42 per share…
HAINHAIN CELESTIAL GROUP INC Nov 9, 2026 · 7:07 AM ET 8-K Hain Celestial reported fiscal Q1 2027 net sales of $260 million, down 29% year over year,… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:07 AM ET	8-K	HAIN HAIN CELESTIAL GROUP INC	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Hain Celestial reported fiscal Q1 2027 net sales of $260 million, down 29% year over year, with organic net sales down 7%. The net loss narrowed to $11 million ($0.12 per share) fr…
CEVACEVA INC Nov 9, 2026 · 7:07 AM ET 8-K Ceva (NASDAQ: CEVA) reported Q3 2026 revenues of $29.1 million, up 2% year-over-year, with… 2.02Results of operations9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:07 AM ET	8-K	CEVA CEVA INC	2.02Results of operations9.01ExhibitsExhibits:EX-99.1 Ceva (NASDAQ: CEVA) reported Q3 2026 revenues of $29.1 million, up 2% year-over-year, with royalty revenues of $12.7 million up 3% YoY and 18% sequentially. The company posted rec…
ZURAZura Bio Ltd Nov 9, 2026 · 7:07 AM ET 8-KZura Bio announced that its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in moderate-t… 8.01Other events9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:07 AM ET	8-K	ZURA Zura Bio Ltd	8.01Other events9.01ExhibitsExhibits:EX-99.1 Zura Bio announced that its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in moderate-to-severe hidradenitis suppurativa failed to meet its primary endpoint of change in abscess…
AMGAFFILIATED MANAGERS GROUP, INC. Nov 9, 2026 · 7:06 AM ET 8-K AMG reported Q3 2026 results on November 9, 2026, with Economic EPS of $9.50 up 56% year o… 2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1	Nov 9, 20267:06 AM ET	8-K	AMG AFFILIATED MANAGERS GROUP, INC.	2.02Results of operations8.01Other events9.01ExhibitsExhibits:EX-99.1 AMG reported Q3 2026 results on November 9, 2026, with Economic EPS of $9.50 up 56% year over year and Adjusted EBITDA of $353.7 million up 41%, while GAAP diluted EPS slipped to $…
FHTXFoghorn Therapeutics Inc. Nov 9, 2026 · 7:06 AM ET 8-K Foghorn Therapeutics reported Q3 2026 results with collaboration revenue of $83.5 million… 2.02Results of operations7.01Reg FD9.01ExhibitsExhibits:EX-99.1EX-99.2	Nov 9, 20267:06 AM ET	8-K	FHTX Foghorn Therapeutics Inc.	2.02Results of operations7.01Reg FD9.01ExhibitsExhibits:EX-99.1EX-99.2 Foghorn Therapeutics reported Q3 2026 results with collaboration revenue of $83.5 million and net income of $58.2 million, a dramatic swing from a $15.8 million net loss a year ear…

Searching Signal8’s SEC filing archive — filings from Oct 2021 onward.

1-20 of 10,000+ filings